Novo Nordisk A/S (NYSE:NVO) Declares Semi-annual Dividend of $0.79

Novo Nordisk A/S (NYSE:NVO) declared a semi-annual dividend on Thursday, February 6th,Wall Street Journal reports. Stockholders of record on Monday, March 31st will be paid a dividend of 0.7874 per share on Tuesday, April 8th. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51.

Novo Nordisk A/S has increased its dividend payment by an average of 25.1% annually over the last three years. Novo Nordisk A/S has a dividend payout ratio of 22.1% meaning its dividend is sufficiently covered by earnings. Analysts expect Novo Nordisk A/S to earn $3.88 per share next year, which means the company should continue to be able to cover its $1.03 annual dividend with an expected future payout ratio of 26.5%.

Novo Nordisk A/S Stock Up 1.7 %

NVO opened at $87.16 on Friday. The business’s fifty day simple moving average is $92.24 and its 200 day simple moving average is $112.01. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market cap of $391.15 billion, a PE ratio of 28.21, a P/E/G ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. As a group, research analysts expect that Novo Nordisk A/S will post 3.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of research reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.